Quantum Computing partners with INmune Bio to apply quantum optimization, AI in Alzheimer’s drug research

By Public Technologies
  • Quantum Computing entered a collaboration with INmune Bio to apply quantum optimization, AI, and analytics to Alzheimer’s drug research.
  • Work will use QCi’s Dirac-3S quantum optimization machine to identify new indications and biomarkers for INmune Bio’s XPro (XPro1595).
  • Project will analyze INmune Bio clinical-trial data alongside public biomedical datasets to prioritize patient groups and potential disease targets.
  • Engagement is QCi’s first commercial customer deal in pharma and biotech, expanding its quantum computing applications into drug development.
  • Program will benchmark quantum optimization results against conventional statistical and machine-learning methods to assess where quantum adds value.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quantum Computing Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610140830PR_NEWS_USPR_____PH71752) on October 14, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.